*  Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma - Full Text View -...
Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Leukemia, T-Cell. Leukemia-Lymphoma, Adult T-Cell. Lymphoma, Large-Cell, Anaplastic. ... Transformed cutaneous T-cell lymphoma (CTCL) to PTCL with systemic involvement (not local skin transformation) ... Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Hepatosplenic T-Cell Lymphoma Mature T-Cell and NK-Cell Non- ... Peripheral T-cell NHL (PTCL) not otherwise specified (NOS). *Anaplastic large cell T-cell lymphoma (ALCL) that is anaplastic ...
  https://clinicaltrials.gov/show/NCT01466881
*  Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma - Full Text View -...
Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Leukemia, T-Cell. Leukemia-Lymphoma, Adult T-Cell. Lymphoma, Large-Cell, Anaplastic. ... Transformed cutaneous T-cell lymphoma (CTCL) to PTCL with systemic involvement (not local skin transformation) ... Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Hepatosplenic T-Cell Lymphoma Mature T-Cell and NK-Cell Non- ... T-cell, Chronic Adult T-cell Leukemia/lymphoma Extranodal Nasal NK/T Cell Lymphoma Anaplastic Large Cell Lymphoma ...
  https://clinicaltrials.gov/ct2/show/study/NCT01466881?show_locs=Y
*  A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma - Tabular View -...
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma. This study has been ... A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL). ... A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma. ... in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. ...
  https://clinicaltrials.gov/ct2/show/record/NCT00866047
*  A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma - Study Results -...
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma. The safety and ... in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. ... Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood ...
  https://clinicaltrials.gov/ct2/show/results/NCT00866047?show_locs=Y
*  Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a...
... is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate ... PURPOSESystemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform ... Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a ... Next Document: Optimized protocol for derivation of human embryonic stem cell lines.. ...
  http://www.biomedsearch.com/nih/Brentuximab-Vedotin-SGN-35-in/22614995.html
*  Adcetris (Brentuximab Vedotin): Side Effects, Interactions, Warning, Dosage & Uses
Table 6: Adverse Reactions Reported in ≥10% of Patients with Relapsed Systemic Anaplastic Large Cell Lymphoma (Study 2). ... Table 12: Efficacy Results in Patients with Systemic Anaplastic Large Cell Lymphoma (Study 2). N = 58. ... Relapsed Systemic Anaplastic Large Cell Lymphoma. 1.8 mg/kg up to a maximum of 180 mg. Intravenous infusion over 30 minutes. ... Large Cell Lymphoma And CD30-expressingMycosis Fungoides. Randomized Clinical Trial In Primary Cutaneous Anaplastic Large Cell ...
  https://www.rxlist.com/adcetris-drug.htm
*  Search of: 'Anaplastic large cell lymphoma' - List Results - ClinicalTrials.gov
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib. *Systemic Anaplastic Large-Cell Lymphoma ... s Lymphoma or Anaplastic Large Cell Lymphoma'. *Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell ... for Systemic Anaplastic Large Cell Lymphoma. *Lymphoma, Large-Cell, Anaplastic ... and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma. *Anaplastic Large Cell Lymphoma ...
  https://clinicaltrials.gov/ct2/results?cond=%22Anaplastic+large+cell+lymphoma%22&show_rss=Y&sel_rss=new14
*  Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and...
... for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) ... by Health Canada in February 2013 for relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. ... the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent ... The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that also ...
  http://www.tmcnet.com/news/2013/02/01/6896249.htm
*  Seattle Genetics - Wikipedia
ADCETRIS used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. SGN-75 - (INN: vorsetuzumab ... for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) Corporate ... Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a ... FDA approval for Brentuximab vedotin for use in treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL ...
  https://en.wikipedia.org/wiki/Seattle_Genetics
*  EC Conditionally Sanctions Lymphoma Treatment | GEN
Adcetris is indicated for Hodgkin lymphoma and systemic anaplastic large cell lymphoma. ... and for treating adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Each approval has ... Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions * Cell-Centered: Scientists Embrace Cell- ... Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions * Cell-Centered: Scientists Embrace Cell- ...
  https://genengnews.com/gen-news-highlights/ec-conditionally-sanctions-lymphoma-treatment/81247567/?kwrd=regulatory
*  Anaplastic large-cell lymphoma - Wikipedia
August 2008). "Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center". ... Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or null lymphocytes. It is ... It has been suggested that ALK-negative anaplastic large-cell lymphomas derive from other T-cell lymphomas that are morphologic ... European T-Cell Lymphoma Study Group (2012). "ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma". Front Oncol ...
  https://en.wikipedia.org/wiki/Anaplastic_large-cell_lymphoma
*  Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed...
Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma ... Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma ... Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma ... About Anaplastic Large Cell Lymphoma. ALCL is a type of aggressive T-cell lymphoma, comprising about 3 percent of all non- ...
  http://www.checkorphan.org/news/millennium-and-seattle-genetics-highlight-data-from-adcetris-brentuximab-vedotin-trial-in-patients-with-newly-diagnosed-systemic-anaplastic-large-cell-lymphoma
*  An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma or...
... in patients with relapsed or refractory Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma. ... B-Cell Lymphoma Moon Shot™ The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to ... and patients with relapsed or refractory anaplastic large cell lymphoma (ALCL). Endpoints The safety endpoints are the type, ... who experience progression of Hodgkin Lymphoma (HL) • To assess the safety and tolerability of brentuximab vedotin • In the US ...
  https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2010-0453.html
*  Chromosome Aberration Case List
Anaplastic large cell lymphoma, systemic type. 92,XX,der(Y)t(Y;5)(q12;q22)x2,+2,add(4)(q35)x2,del(6)(q23q25)x2,-9,add(17) (p11 ... Diffuse large B-cell lymphoma. 49,XX,+X,t(2;5)(q24;q31),t(3;13)(p13;q33),t(3;14)(q27;q32),inv(5)(p15q12), del(6)(q21q25),t(7;19 ... Diffuse large B-cell lymphoma. 44-50,XY,add(2)(p12),+3,der(3)add(3)(p12)add(3)(q24)x2,del(5)(q15q35),add (6)(q15),del(6)(q14q25 ... Diffuse large B-cell lymphoma. 46,-X,-Y,-1,add(1)(q?),-2,add(4)(q?),-6,del(6)(q25),-8,-10,-12,-13,t(13;15), -14,-15,-16,-17,-18 ...
  https://cgap.nci.nih.gov/Chromosomes/CytList?breakpoint=6q25&page=1
*  Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody-Drug Conjugates | SpringerLink
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell ... Generation of glyco-engineered BY2 cell lines with decreased expression of plant-specific glycoepitopes. Protein Cell. 2011;2(1 ... T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534- ... lymphoma. Nat Biotechnol. 2012;30(7):631-7.PubMedCrossRefGoogle Scholar ...
  https://link.springer.com/article/10.1007%2Fs40259-014-0096-z
*  Brentuximab (Intravenous Route) Before Using - Mayo Clinic
Brentuximab injection is used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma, which are blood cancers. ... It is given to patients who have received a bone marrow (autologous stem cell) transplant or other cancer treatments that did ... Brentuximab interferes with the growth of cancer cells, which are then destroyed by the body. ...
  https://www.mayoclinic.org/drugs-supplements/brentuximab-intravenous-route/before-using/drg-20075154?p=1
*  Articles Added on October 10, 2012
Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the ... ... PURPOSESystemic anaplastic large-cell lymphoma (ALCL) is a T-cell lymphoma, whose anaplastic lymphoma kinase (ALK) expression ... Cell therapy is an attractive approach for treating muscle diseases, although this is hampered by the need to generate large ... Studies with a number of viral systems have shown, on the basis of the ability of a host to prime naïve T cells, that viral ...
  http://www.biomedsearch.com/added/20121010-p9.html
*  Why Seattle Genetics Dropped - AOL Finance
Adcetris for treatment-resistant forms of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Adcetris received Food ... The first tests Adcetris for patients at risk of residual Hodgkin lymphoma following a stem cell transplant. The second ...
  https://www.aol.com/2013/02/13/why-seattle-genetics-dropped/
*  Brentuximab vedotin | Leukemia and Lymphoma Society
Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ... Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30- expressing mycosis fungoides (MF) who have received prior ... The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission ... Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after ...
  https://www.lls.org/treatment/types-of-treatment/chemotherapy-and-other-drug-therapies/drug-listings/brentuximab-vedotin
*  ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell...
Systemic anaplastic large-cell lymphoma: results from the Non-Hodgkin's Lymphoma Classification Project. Am J Hematol 2001;67: ... Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002;20:3691-3702. ... Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor ... Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. ...
  http://www.bloodjournal.org/content/111/12/5496.long?sso-checked=true
*  Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates | Molecular Cancer...
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell ... Hodgkin lymphomas); Karpas299 (anaplastic large cell lymphoma, originally provided by Dr. Abraham Karpas, University of ... diffuse large B-cell lymphoma) cell lines. L428, Karpas299, SU-DHL-4, and WSU-DLCL2 cell lines were obtained from DSMZ. Ramos ... and L428 lymphoma cell lines were obtained in 2012. The CD19+ Ramos, SU-DHL-4, WSU-DLCL2, and RL lymphoma cell lines were ...
  http://mct.aacrjournals.org/content/16/1/116?utm_source=jan3spot&utm_medium=carousel&utm_campaign=0343
*  Brentuximab vedotin - Wikipedia
... and systemic anaplastic large cell lymphoma (ALCL). It selectively targets tumor cells expressing the CD30 antigen, a defining ... Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma ... who have received prior systemic therapy. This approval is for patients with primary cutaneous anaplastic large cell lymphoma ( ... be made available more generally for the first-line treatment of relapsed or refractory systemic anaplastic large cell lymphoma ...
  https://en.wikipedia.org/wiki/Brentuximab_vedotin
*  Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707 ...
Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016; 101(1):e27-29. ... anaplastic lymphoma kinase-positive anaplastic large cell lymphoma, n=2; and anaplastic lymphoma kinase-negative anaplastic ... angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), and ... Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies ...
  http://www.haematologica.org/content/102/12/2097
*  Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Ma - AOL Finance
... in Front-line Mature T-Cell Lymphomas (MTCL) -100 Percent Objective Response Rate, Including 88 Percent ... Including Systemic Anaplastic Large Cell Lymphoma and Other Types of Peripheral T-cell Lymphomas- ... Other mature T-cell lymphomas include PTCL, angioimmunoblastic T-cell lymphoma and adult T-cell lymphoma. ... ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma ( ...
  https://www.aol.com/2012/12/09/seattle-genetics-reports-data-from-phase-i-trial-o/